Carcinosarcoma of the Bladder: A Case Report and Review of the Literature

Atılgan, Doğan; Gençten, Yusuf

doi:10.1155/2013/716704

Cited by 5 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent location of sarcomatoid urothelial carcinoma is the lateral wall of the bladder. However, previous studies have shown the commonest location to be trigone of the bladder which gives evidence for the origin of the tumor from wolffian body [5]. pattern of distribution with base showing increased cellularity and towards the surface are hypocellular and myxoid regions [7].…”

Section: Discussionmentioning

confidence: 92%

Sarcomatoid Urothelial Carcinoma of Urinary Bladder – A Rare Case Report

Shanthi¹,

Rao²,

Grandhi³

et al. 2016

IJCR

View full text Add to dashboard Cite

Sarcomatoid variant of urothelial carcinoma of urinary bladder is a rare tumor which exhibits epithelial and mesenchymal differentiation of tumor cells both morphologically and immunohistochemically. Cyclophosphamide treatment and radiation therapy are associated with this tumors. This tumor is considered to be the aggressive variant of transitional cell carcinomas of the bladder. Treatment for this aggressive tumor is radical surgical excision with chemoradiation. We report a case of 47-yearfemale presenting with dysuria and hematuria. On imaging, heterogeneously enhancing hyperdense lesion in bladder was noted which was diagnosed as sarcomatoid urothelial carcinoma on histopathological examination.

show abstract

Section: Discussionmentioning

confidence: 92%

Sarcomatoid Urothelial Carcinoma of Urinary Bladder – A Rare Case Report

Shanthi¹,

Rao²,

Grandhi³

et al. 2016

IJCR

View full text Add to dashboard Cite

show abstract

“…Most of the available literature is case reports and literature reviews with small numbers of cases. [6][7][8][9] To the best of our knowledge, no prospective study or clinical trial on BCS has been published, and only two retrospective studies published in English included a large sample size. [12][13][14] One identified 221 BCS patients in the SEER 17 registries diagnosed between 1973 and 2004; the other enrolled 3007 patients with genitourinary sarcomas diagnosed from 1973 to 2015 from the SEER 18 registries.…”

Section: Subgroup Analysismentioning

confidence: 99%

“…5 Published case reports indicate that BCS has high rates of recurrence and metastasis, and patients present with poor differentiation and advanced stage, leading to poor prognosis. [6][7][8][9] In addition, BCS is thought to have outcomes similar to those of bladder TCC. 10 The sample sizes of previous studies are too small to provide conclusive results.…”

Section: Introductionmentioning

confidence: 99%

“…10 The sample sizes of previous studies are too small to provide conclusive results. [6][7][8][9][10] Therefore, a large population-based study with the intent to compare BCS and conventional bladder cancer (TCC, SCC or AC) is warranted. In this study, we reviewed the Surveillance, Epidemiology, and End Results (SEER) database to compare clinicopathological characteristics and outcomes of patients with BCS and conventional bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

2022

View full text Add to dashboard Cite

Background Case reports of bladder carcinosarcoma (BCS) indicate high rates of recurrence and metastasis and poor prognosis. However, the differences in clinicopathologic characteristics and prognosis between BCS and conventional bladder cancer histologies (transitional cell carcinoma [TCC], squamous cell carcinoma [SCC] and adenocarcinoma [AC]) have not been fully clarified in a large study. Therefore, we conducted a large population‐based study to further investigate these differences. Patients and methods Information on patients with BCS and conventional bladder cancer (TCC, SCC or AC) was extracted from the Surveillance, Epidemiology, and End Results database. Categorical variables were compared using Pearson's chi‐squared test or Fisher's exact test. Survival analysis was carried out using the Kaplan–Meier method, and differences in survival were assessed using the log‐rank test. Propensity score matching analysis was conducted to calibrate the differences between the baseline characteristics, after which Cox regression analysis was applied to calculate the hazard ratios and 95% confidence intervals of BCS compared to other subtypes. Subgroup analysis and related interaction were tested to evaluate the consistency and heterogeneity of results. Results We enrolled 152 patients with BCS and 180,196 patients with TCC, SCC or AC. Our results showed that BCS was associated with poor differentiation, advanced stage and an unfavourable overall survival and cancer‐specific survival. BCS had a worse prognosis than TCC and AC, but no statistically significant difference in survival was noted between BCS and SCC. Conclusions BCS is a more aggressive bladder cancer than TCC and AC but is comparable to SCC. These findings broaden our understanding of BCS and may be helpful in clinical practice.

show abstract

“…Carcinosarcomas might arise in in different organs like the oropharynx, the lung, the male genital system and the female reproductive organs with the so-called Malignant Mixed Müllerian tumour, the most often detected type of carcinosarcoma 3 , 4 . Carcinosarcomas within the bladder are very rare, accounting for only approximately 0.11% of all primary bladder tumours 5 . Epidemiologically carcinosarcomas of the bladder are a tumour entity that occurs more often in elder males in their seventh decade 6 , 7 .…”

Section: Introductionmentioning

confidence: 99%

First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder

Eberhard

Hirsch

Schilling

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Carcinosarcoma of the urinary bladder is a very rare and aggressive subtype of bladder cancer with poor prognosis. Characteristically carcinosarcomas exhibit biphasic nature with both epithelial and mesenchymal differentiation. Limited information is available regarding its clinical features and appropriate treatments due to its rarity. Development of tumour models can further our understanding of bladder carcinosarcoma. We report establishment and characterization of the first-ever bladder carcinosarcoma cell line MaS-3. It is established by the outgrow method from 86 year-old caucasian male who underwent a radical pelvic resection after neoadjuvant radiotherapy. MaS-3 showed carcinosarcoma profile with high conformity with to the original tumour in terms of immunocytochemistry. Proteome analysis also aligned the MaS-3 cell line with the carcinosarcoma specimen rather than corresponding non-malignant tissue. Chemotherapy sensitivity testing revealed a great sensitivity of MaS-3 growth to 5-Fluorouracil, Gemcitabine and Cisplatin, with almost no impact of Irinotecan. Additionally, the suitability of MaS-3 for 3D in vitro experiments was also demonstrated. The newly established cell line MaS-3 shows typical characteristics of the tumour and may thus be a useful in vitro model system for studying the tumour biology and developing future of treatments of this rare but very aggressive entity.

show abstract

Carcinosarcoma of the Bladder: A Case Report and Review of the Literature

Cited by 5 publications

References 10 publications

Sarcomatoid Urothelial Carcinoma of Urinary Bladder – A Rare Case Report

Sarcomatoid Urothelial Carcinoma of Urinary Bladder – A Rare Case Report

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder

Contact Info

Product

Resources

About